Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een studie van Seltorexant in vergelijking met Quetiapine XR als aanvullende therapie bij antidepressiva bij volwassen en oudere deelnemers met ernstige depressieve stoornis met slapeloosheidssymptomen die onvoldoende hebben gereageerd op antidepressiva

11 november 2026 bijgewerkt door: Janssen Research & Development, LLC

Dubbelblinde, gerandomiseerde studie met parallelle groepen met verlengde afgifte van quetiapine als comparator om de werkzaamheid en veiligheid van Seltorexant 20 mg te evalueren als aanvullende therapie bij antidepressiva bij volwassen en oudere patiënten met een ernstige depressieve stoornis met slapeloosheidssymptomen die onvoldoende hebben gereageerd op antidepressiva

The purpose of this study is to assess the efficacy of seltorexant compared with quetiapine extended-release (XR) as adjunctive therapy to an antidepressant drug in treatment response in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).

Studie Overzicht

Gedetailleerde beschrijving

Major depressive disorder (MDD) is a common, serious, recurrent disorder. Seltorexant (JNJ-42847922) is a potent and selective antagonist of the human orexin-2 receptor (OX2R) that is being developed for the adjunctive treatment of MDDIS. The hypothesis for this study is that seltorexant is superior to quetiapine XR in leading to a response after 26 weeks of treatment (greater than or equal to [>=] 50 percent [%] improvement on baseline Montgomery Asberg Depression Rating Scale [MADRS] total score), when administered as adjunctive treatment to an antidepressant in adult and elderly participants with MDDIS who have had an inadequate response to treatment with an SSRI/SNRI. The study will be conducted in 3 phases: a screening phase (up to 30 days), a double-blind (DB) treatment phase (26 weeks), and a post treatment follow-up phase (7 to 14 days after the end of DB treatment phase for all participants, and up to 196 days from baseline for participants who stop study treatment early). The total study duration for each participant will be approximately 32 weeks. Efficacy, safety, pharmacokinetics, and biomarkers will be assessed at specified time points during this study.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

757

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Buenos Aires, Argentinië, 1058AAJ
        • CENydET - Centro Neurobiologico y de Stress Traumatico
      • Buenos Aires, Argentinië, C1405BOA
        • FunDaMos
      • Buenos Aires, Argentinië, 1199
        • Hospital Italiano
      • Ciudad Autonoma Buenos Aires, Argentinië, C1428AQK
        • Hospital Fleni
      • Córdoba, Argentinië, X5004AOA
        • Instituto Privado Kremer
      • Córdoba, Argentinië, 5000
        • Fundacion Lennox
      • Córdoba, Argentinië, X5006IKK
        • Centro Medico Luquez
      • La Plata, Argentinië, Thanks
        • Clinica Privada de Salud Mental Santa Teresa de Ávila
      • La Plata, Argentinië, 1902
        • CENPIA
      • Mendoza, Argentinië, M5502AWY
        • CENAIN
      • San Miguel de Tucumán, Argentinië, 4000
        • Clinica Mayo de UMCB
      • Bruges, België, 8310
        • AZ Sint-Lucas
      • Sint-Niklaas, België, 9100
        • AZ Nikolaas
      • Pleven, Bulgarije, 5800
        • Medical Center Medconsult-Pleven
      • Plovdiv, Bulgarije, 4028
        • MC 'Hipokrat - N', EOOD
      • Rousse, Bulgarije, 7003
        • Mental Health Center - Rousse
      • Sofia, Bulgarije, 1680
        • Medical Center Intermedica, OOD
      • Sofia, Bulgarije, 1113
        • Medical Center St. Naum
      • Sofia, Bulgarije, 1784
        • MC 'Synexus Sofia' EOOD
      • Stara Zagora, Bulgarije, 6003
        • UMHAT Prof. Dr. St. Kirkovich AD
      • Stara Zagora, Bulgarije, 6000
        • MC 'Synexus Sofia' EOOD
      • Tzarev Brod, Bulgarije, 9747
        • State Psychiatric Hospital - Tzarev Brod
      • Varna, Bulgarije, 9020
        • Diagnostic Consulting Center Mladost - M Varna
      • Veliko Tarnovo, Bulgarije, 5000
        • Mental Health Center - Veliko Tarnovo EOOD
    • Nova Scotia
      • Sydney, Nova Scotia, Canada, B1P 1E1
        • A.K. Munshi Medical Inc.
    • Ontario
      • Toronto, Ontario, Canada, M3J 2C5
        • Canadian Phase Onward
    • Quebec
      • Montreal, Quebec, Canada, H1M 1B1
        • Clinique Force Medic (GCP Trials)
      • Jelgava, Letland, LV-3008
        • The Mental Hospital of Jelgava Ģintermuiža - Psychiatry
      • Liepāja, Letland, LV-3401
        • L. Keruze Practice in Psychiatry
      • Outpatient Centre of Psychiatry, Letland, LV-4601
        • Hospital of Rezekne
      • Riga, Letland, LV-1002
        • Riga Centre of Psychiatry and Narcology
      • Kaunas, Litouwen, 48259
        • Kaunas Silainiu Outpatient Clinic, Public Institution
      • Kaunas, Litouwen, 53136
        • Republic Kaunas Hospital
      • Kaunas, Litouwen, LT-44279
        • Romuvos Klinika, JSC
      • Kaunas, Litouwen, LT-50009
        • Hospital of Lithuanian University of Health Sciences Kaunas Clinics
      • Vilnius, Litouwen, 09112
        • Zirmunai Mental Health Center, Public Institution
      • Vilnius, Litouwen, 10309
        • Vilnius Mental Health Center
      • Vilnius, Litouwen, 10204
        • Antakalnis Psychiatric Consultation Centre, Public Institution
      • Šilutė, Litouwen, 99176
        • Medical Center Puriena JSC
      • Ipoh, Maleisië, 30990
        • Hospital Raja Permaisuri Bainun
      • Johor Bahru, Maleisië, 81200
        • Hospital Permai
      • Pulau Pinang, Maleisië, 10990
        • Hospital Pulau Pinang
      • Seremban, Maleisië, 70300
        • Hospital Tuanku Jaafar
      • Hlevakha, Oekraïne, 8631
        • MNCE of Kyiv RC Regional Psychiatric and Narcological Medical Association
      • Kharkiv, Oekraïne, 61068
        • Mnpe of Kharkiv Regional Council 'Regional Clinical Psychiatric Hospital #3'
      • Kyiv, Oekraïne, 04080
        • Kyiv Territorial Medical Incorporation 'Psychiatry'
      • Kyiv, Oekraïne, 1030
        • Railway Clinical Hospital #1 of Kiev Railway station of DTGO 'South-Western Railway'
      • Kyiv, Oekraïne, 1034
        • Medical Center Health and Happy
      • Nove, Oekraïne, 25491
        • Mnpe 'Regional Clinical Psychiatric Hospital of Kirovohrad Regional Council'
      • Ternopil, Oekraïne, 46020
        • Ternopil RCCPH Depts of Psychiatry #2 (m) & Psychiatry #4 (f) Ternopil I.Ya. Gorbachevskyi SMU
      • Zaporizhzhya, Oekraïne, 69600
        • Zaporizhzhia Regional Clinical Hospital
      • Bełchatów, Polen, 97-400
        • Gabinet Lekarski Psychiatryczny Ireneusz Kaczorowski
      • Bialystok, Polen, 15-464
        • Wlokiennicza MED Specjalistyczna Praktyka Lekarska dr n.med. Tomasz Markowski
      • Bydgoszcz, Polen, 85-080
        • Przychodnia Srodmiescie SP. z o.o.
      • Gdansk, Polen, 80 546
        • Centrum Badan Klinicznych PI House sp z o o
      • Lodz, Polen, 90-009
        • Specjalistyczna Indywidualna Praktyka Lekarska
      • Lodz, Polen, 90-368
        • CCBR - Lodz - PL
      • Lublin, Polen, 20-582
        • Specjalistyczna Praktyka Lekarska Marek Domanski
      • Poznan, Polen, 60-702
        • Synexus Polska Sp. z.o.o. Oddzial w Poznaniu
      • Warsaw, Polen, 01 737
        • Specjalistyczny Osrodek Medycyny Wieku Dojrzalego Sp z o.o.
      • Warsaw, Polen, 02 957
        • Instytut Psychiatrii I Neurologii
      • Engel's, Rusland, 413124
        • Engels psychiatric hospital
      • Kemerovo, Rusland, 650036
        • Kemerovo Regional Clinical Psychiatric Hospital
      • Lipetsk Region, Rusland, 399313
        • GUZ Lipetsk Regional psychoneurological Hospital #1
      • Moscow, Rusland, 105082
        • JSC Scientific Centre of Personalized Medicine
      • Moscow, Rusland, 107076
        • FSI Moscow SRI of Psychiatry of Minzdravsocrazvitia
      • Moscow, Rusland, 107076
        • Moscow Scientific Research Institute of Psychiatry
      • Omsk, Rusland, 644070
        • Clinical Psychiatry Hospital n.a. N.N. Solodovnikov
      • Saint Petersburg, Rusland, 192019
        • St-Petersburg Bekhterev Psychoneurological Research Institute
      • Tomsk, Rusland, 634009
        • Klinika StoLet Ltd
      • Yekaterinburg, Rusland, 620030
        • Sverdlov Regional Psychiatric Clinical Hospital
      • Belgrade, Servië, 11000
        • University Clinical Center of Serbia
      • Belgrade, Servië, 11000
        • General Hospital Euromedik
      • Belgrade, Servië, 11000
        • University Clinical Hospital Center Dr Dragisa Misovic- Dedi
      • Belgrade, Servië, 11000
        • General Hospital Acibadem Bel Medic
      • Belgrade, Servië, 11000
        • Institute of Mental Health Serbia
      • Kovin, Servië, 26220
        • Special Neuropsychiatric Hospital Kovin
      • Kragujevac, Servië, 34000
        • University Clinical Center Kragujevac
      • Niš, Servië, 18000
        • Clinical Center Nis
      • Novi Kneževac, Servië, 23330
        • Specialized Hospital for Neuropsychiatric Diseases Sveti Vracevi
      • Banská Bystrica, Slowakije, 97401
        • Psychomed-Svatosavsky, s.r.o.
      • Bojnice, Slowakije, 97201
        • Nemocnica s poliklinikou Prievidza so sidlom v Bojniciach
      • Košice, Slowakije, 040 11
        • Epamed sro
      • Liptovský Mikuláš, Slowakije, 03123
        • Liptovska Nemocnica S Poliklinikou Mudr. Ivana Stodolu
      • Rimavská Sobota, Slowakije, 97901
        • Psychiatricka Ambulancia Psycholine S.R.O.
      • Trenčín, Slowakije, 91101
        • FN Trencin
      • Trenčín, Slowakije, 91108
        • Pro mente sana s.r.o.
      • Žilina, Slowakije, 1207
        • Fakultna nemocnica s poliklinikou v Ziline
      • Brno, Tsjechië, 60200
        • Psychiatricka ambulance Saint Anne s.r.o.
      • Hradec Králové, Tsjechië, 500 09
        • NeuropsychiatrieHK, s.r.o.
      • Pilsen, Tsjechië, 301 00
        • A Shine S R O
      • Prague, Tsjechië, 100 00
        • Clintrial s r o
      • Prague, Tsjechië, 160 00
        • NeuropsychiatrieHK, s.r.o.
      • Prague, Tsjechië, 10000
        • AD71 s.r.o.
      • Prague, Tsjechië, 186 00
        • Institut Neuropsychiatricke pece
      • Derby, Verenigd Koninkrijk, DE22 3LZ
        • Kingsway Hospital
      • Greater Manchester, Verenigd Koninkrijk, M15 6SX
        • Synexus
      • Harrogate, Verenigd Koninkrijk, HG1 2PW
        • Garden Valleys Resource Centre
      • London, Verenigd Koninkrijk, SE5 8EF
        • Kings College Hospital NHS Trust
      • Redruth, Verenigd Koninkrijk, TR15 2SP
        • Cornwall Partnership Foundation Trust
    • Alabama
      • Birmingham, Alabama, Verenigde Staten, 35233
        • University of Alabama at Birmingham
    • Arizona
      • Tucson, Arizona, Verenigde Staten, 85712
        • SW Biomedical Research LLC
    • California
      • Culver City, California, Verenigde Staten, 90230
        • Proscience Research Group
      • Encino, California, Verenigde Staten, 91316
        • Pharmacology Research Institute
      • Garden Grove, California, Verenigde Staten, 92845
        • Collaborative NeuroScience Network
      • Long Beach, California, Verenigde Staten, 90806
        • Collaborative NeuroScience Network
      • Los Alamitos, California, Verenigde Staten, 90720
        • Pharmacology Research Institute
      • Los Angeles, California, Verenigde Staten, 90025
        • CalNeuro Research
      • Newport Beach, California, Verenigde Staten, 92660
        • Pharmacology Research Institute
      • Orange, California, Verenigde Staten, 92868
        • NRC Research Institute
      • Orange, California, Verenigde Staten, 92868
        • Pacific Neuropsychiatric Specialists
      • Pico Rivera, California, Verenigde Staten, 90660
        • CNRI-Los Angeles, LLC
      • Rancho Cucamonga, California, Verenigde Staten, 91730
        • Prospective Research Innovations Inc
      • Redlands, California, Verenigde Staten, 92374
        • Anderson Clinical Research
      • San Diego, California, Verenigde Staten, 92103
        • University of California at San Diego
      • Santa Ana, California, Verenigde Staten, 92705
        • CI Trials
      • Santa Ana, California, Verenigde Staten, 91704
        • National Research Institute
      • Santee, California, Verenigde Staten, 92071
        • CMB Clinical Trials
      • Sherman Oaks, California, Verenigde Staten, 91403
        • Schuster Medical Research Institute
      • Upland, California, Verenigde Staten, 91786
        • Pacific Clinical Research Medical Group
    • Connecticut
      • Hartford, Connecticut, Verenigde Staten, 06102
        • Hartford Hospital
    • Florida
      • Doral, Florida, Verenigde Staten, 33166
        • Moonshine Research Center, Inc
      • Hallandale, Florida, Verenigde Staten, 33009
        • Velocity Clinical Research, Hallandale Beach
      • Hialeah, Florida, Verenigde Staten, 33012
        • Indago Research & Health Center Inc
      • Hialeah, Florida, Verenigde Staten, 33012
        • New Life Medical Research Center, Inc.
      • Hialeah, Florida, Verenigde Staten, 33013
        • Amedica Research Institute Inc
      • Lakeland, Florida, Verenigde Staten, 33803
        • Meridien Research
      • Miami, Florida, Verenigde Staten, 33122
        • Premier Clinical Research
      • Miami, Florida, Verenigde Staten, 33125
        • Global Medical Institutes
      • Miami, Florida, Verenigde Staten, 33137
        • Miami Jewish Health System
      • Orlando, Florida, Verenigde Staten, 32806
        • Synexus Research Orlando
      • Orlando, Florida, Verenigde Staten, 23801
        • Clinical Neuroscience Solutions
      • Tampa, Florida, Verenigde Staten, 33612
        • University of South Florida
      • The Villages, Florida, Verenigde Staten, 32162
        • Compass Research LLC-Bioclinica Research
    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30331
        • Atlanta Center for Medical Research
      • Atlanta, Georgia, Verenigde Staten, 30328
        • Synexus Clinical Research US Inc
      • Decatur, Georgia, Verenigde Staten, 30030
        • iResearch Atlanta LLC
      • Marietta, Georgia, Verenigde Staten, 30060
        • Psych Atlanta, P.C.
    • Illinois
      • Chicago, Illinois, Verenigde Staten, 60634
        • Chicago Research Center
      • Libertyville, Illinois, Verenigde Staten, 60048
        • Capstone Clinical Research
      • Lisle, Illinois, Verenigde Staten, 60532
        • Alexian Brothers Health System
      • Naperville, Illinois, Verenigde Staten, 60563
        • Baber Research Group
      • Oakbrook Terrace, Illinois, Verenigde Staten, 60618
        • Lemah Creek Clinical Research
    • Kansas
      • Wichita, Kansas, Verenigde Staten, 67214
        • Ascension via Christi Research
    • Louisiana
      • New Orleans, Louisiana, Verenigde Staten, 70115
        • Riverstar Research
    • Maryland
      • Baltimore, Maryland, Verenigde Staten, 21208
        • Pharmasite Research, Inc.
    • Massachusetts
      • New Bedford, Massachusetts, Verenigde Staten, 02740
        • BTC of New Bedford
      • Roslindale, Massachusetts, Verenigde Staten, 02135
        • Boston Clinical Trials & Medical Research
    • Missouri
      • O'Fallon, Missouri, Verenigde Staten, 63368
        • Psychiatric Care and Research Center (PCRC)
    • New Jersey
      • Toms River, New Jersey, Verenigde Staten, 08755
        • Bio Behavioral Health
    • New York
      • Brooklyn, New York, Verenigde Staten, 11235
        • SPRI Clinical Trials, LLC
      • New York, New York, Verenigde Staten, 10128
        • The Medical Research Network, LLC
      • New York, New York, Verenigde Staten, 10017
        • Fieve Clinical Research Inc
      • Rochester, New York, Verenigde Staten, 14618 1609
        • Finger Lakes Clinical Research
      • Staten Island, New York, Verenigde Staten, 10312
        • Richmond Behavioral Associates
    • North Carolina
      • Durham, North Carolina, Verenigde Staten, 27701
        • Velocity Clinical Research, Inc.
    • Ohio
      • Cincinnati, Ohio, Verenigde Staten, 45219
        • University of Cincinnati, Dept of Psychiatry & Behavioral Neuroscience
      • Dayton, Ohio, Verenigde Staten, 45417
        • Midwest Clinical Research Center
      • North Canton, Ohio, Verenigde Staten, 44720
        • Neuro Behavioral Clinical Research
    • Oklahoma
      • Oklahoma City, Oklahoma, Verenigde Staten, 73112
        • Sooner Clinical Research
      • Oklahoma City, Oklahoma, Verenigde Staten, 73118
        • Paradigm Research Professionals, LLC
    • Pennsylvania
      • Pine Hill, Pennsylvania, Verenigde Staten, 08021
        • Suburban Research Associates
      • Scranton, Pennsylvania, Verenigde Staten, 18503
        • Global Medical Institutes
    • South Carolina
      • Mt. Pleasant, South Carolina, Verenigde Staten, 29464
        • Coastal Carolina Research Center
    • Texas
      • Bellaire, Texas, Verenigde Staten, 77401
        • West Houston Clinical Research Service
      • Fort Worth, Texas, Verenigde Staten, 76104
        • North Texas Clinical Trials
      • Mansfield, Texas, Verenigde Staten, 76054
        • Hawkins Psychiatry, PC
      • The Woodlands, Texas, Verenigde Staten, 77381
        • Family Psychiatry of The Woodlands
      • Wichita Falls, Texas, Verenigde Staten, 76309
        • Grayline Research Center
    • Utah
      • Clinton, Utah, Verenigde Staten, 84015
        • Alpine Research Organization
      • Draper, Utah, Verenigde Staten, 84020
        • Cedar Clinical Research
    • Virginia
      • Charlottesville, Virginia, Verenigde Staten, 22903
        • University of Virginia
    • Washington
      • Bellevue, Washington, Verenigde Staten, 98007
        • Northwest Clinical Research Center
      • Everett, Washington, Verenigde Staten, 98201
        • Core Clinical Research
    • Wisconsin
      • Waukesha, Wisconsin, Verenigde Staten, 53188
        • Cary J. Kohlenberg, MD, SC, dba, IPC Research.

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 74 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Meet diagnostic and statistical manual of mental disorders-5th edition (DSM-5) diagnostic criteria for major depressive disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the structured clinical interview for DSM-5 Axis I disorders-clinical trials version (SCID-CT) diagnosed with first depressive episode prior to age 60. The length of the current depressive episode must be less than or equal to (<=) 24 months
  • Have had an inadequate response to at least 1 but no more than 2 antidepressants, administered at an adequate dose and duration in the current episode of depression. The current antidepressant cannot be the first antidepressant treatment for the first lifetime episode of depression. An inadequate response is defined as less than (<) 50 percent (%) reduction but with some improvement (that is, improvement greater than [>] 0%) in depressive symptom severity with residual symptoms present other than insomnia, and overall good tolerability, as assessed by the Massachusetts General Hospital-Antidepressant Treatment Response Questionnaire (MGH-ATRQ)
  • Is receiving and tolerating well any one of the following selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) for depressive symptoms at screening, in any formulation and available in the participating country: citalopram, duloxetine, escitalopram, fluvoxamine, fluoxetine, milnacipran, levomilnacipran, paroxetine, sertraline, venlafaxine, desvenlafaxine, vilazodone, or vortioxetine at a stable dose (at or above therapeutic dose level) for at least 6 weeks, and for no greater than 18 months in the current episode
  • Have a hamilton depression rating scale (HDRS)-17 total score greater than or equal to (>=) 20 at the first screening interview, must not demonstrate a clinically significant improvement (that is, an improvement of > 20% on their HDRS-17 total score) from the first to the second independent HDRS-17 rating, and must have a HDRS-17 total score >18 at the second screening interview
  • Have a patient version insomnia severity index (ISI) total score >= 15 as well as a clinician version of the ISI total score >= 15 at the second screening visit
  • Body mass index (BMI) between 18 and 40 kilogram per meter square (kg/m^2), inclusive (BMI=weight/height^2)
  • Participant must be medically stable on the basis of the following: physical examination, vital signs (including blood pressure), and 12-lead electrocardiogram (ECG) performed at screening and baseline

Exclusion Criteria:

  • Has a recent (last 3 months) history of, or current signs and symptoms of, severe renal insufficiency (creatinine clearance [CrCl] less than [<] 30 milliliter per minute [mL/min]); clinically significant or unstable cardiovascular, respiratory, gastrointestinal, neurologic, hematologic, rheumatologic, immunologic or endocrine disorders. uncontrolled Type 1 or Type 2 diabetes mellitus
  • Has a history of treatment-resistant MDD, defined as a lack of response to 2 or more adequate antidepressant treatments in the current episode, as indicated by no or minimal (<25% improvement in symptoms) when treated with an antidepressant of adequate dose (per MGH-ATRQ) and duration (at least 6 weeks)
  • Has history or current diagnosis of a psychotic disorder, bipolar disorder, intellectual disability, autism spectrum disorder, borderline personality disorder, somatoform disorders
  • Has a history of moderate to severe substance use disorder including alcohol use disorder according to DSM-5 criteria within 6 months before screening
  • Has any significant primary sleep disorder, including but not limited to obstructive sleep apnea, restless leg syndrome, or parasomnias. Participants with insomnia disorder are allowed

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Dubbele

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Seltorexant

Adult participants will receive seltorexant once daily from Day 1-7 and together with matching placebo from Day 8 till Day 182. Elderly participants will receive seltorexant once daily from Day 1-3 and together with matching placebo from Day 4 till Day 182.

Participants will receive seltorexant over-encapsulated tablet orally.

Participants will receive placebo over-encapsulated tablet matching to seltorexant orally.

Actieve vergelijker: Quetiapine Extended-Release (XR)

Adult participants will receive quetiapine XR once daily from Day 1-2, followed by an increase in dose from Day 3-7, and from Day 8-14 together with matching placebo. After Day 14, quetiapine XR twice daily from Day 14 till Day 182. Elderly participants will receive quetiapine XR once daily from Day 1-3 and twice from Day 4-7, followed by an increase in dose once daily from Day 8-14 together with matching placebo. After Day 14 till Day 182, quetiapine XR will be adjusted by investigator based on the participant's clinical response and tolerability.

Participants will receive quetiapine XR capsule orally.

Participants will receive placebo capsule matching to quetiapine XR orally.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Participants Who Achieved Response (Greater Than or Equal to [>=50] Percent Improvement in Montgomery-Asberg Depression Rating Scale [MADRS] Total Score From Baseline) at Week 26
Tijdsspanne: Week 26

Percentage of participants who achieved response at Week 26 was reported. Responders were defined as participants with >= 50 percent (%) improvement in the MADRS total score from baseline. MADRS was a clinician-administered scale designed to measure depression severity and detected changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.

Week 26

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change From Baseline to Week 26 in Weight
Tijdsspanne: Baseline (Day 1) and Week 26

Change from baseline to Week 26 in weight was reported.

Baseline (Day 1) and Week 26
Time to Potentially Treatment Related Discontinuation of Study Drug
Tijdsspanne: From first dose of study drug (Day 1) up to Week 30

Time to potentially treatment related discontinuation of study drug was reported. Time to discontinuation of study drug was defined as the number of days from the first dose of study drug to the last dose of study drug. Potentially treatment related discontinuation of study drug was defined as all study drug discontinuations excluding the potentially non-treatment related discontinuations (such as, loss of insurance for antidepressant therapy, movement/travel out of the area, change of work-schedule being unable to accommodate visit schedule, family circumstances, site terminated by sponsor, study terminated by sponsor). Kaplan-Meier estimate was used.

From first dose of study drug (Day 1) up to Week 30
Change From Baseline to Week 26 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Tijdsspanne: Baseline (Day 1) and Week 26

Change from baseline to Week 26 in MADRS total score were reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.

Baseline (Day 1) and Week 26
Change From Baseline to Week 26 in MADRS-6 Total Score
Tijdsspanne: Baseline (Day 1) and Week 26

Change from baseline to Week 26 in MADRS-6 total score was reported. The MADRS-6 scale was a clinician-administered questionnaire used to measure the severity of MDD symptoms. The MADRS-6 scale was a subset of the MADRS-10 scale, comprised of the following individual questionnaire items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), the overall score ranged from 0 to 36, higher scores represented a more severe condition.

Baseline (Day 1) and Week 26
Change From Baseline to Week 26 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score
Tijdsspanne: Baseline (Day 1) and Week 26

The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. MADRS-WOSI was defined as the full MADRS without the sleep item. The MADRS-WOSI scale consisted of 9 items (apparent sadness, reported sadness, inner tension, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS-WOSI total score was the sum of scores from individual question items, which ranged from 0 to 54, higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement.

Baseline (Day 1) and Week 26
Change From Baseline to Week 26 in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score
Tijdsspanne: Baseline (Day 1) and Week 26

Change from baseline to Week 26 in PHQ-9 total score was reported. The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the diagnostic and statistical manual of mental disorders-5th edition (DSM-5) major depressive disorder (MDD) criteria. Each item was rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. Negative changes in PHQ-9 total score indicated improvement.

Baseline (Day 1) and Week 26
Percentage of Participants With MADRS Total Score Less Than or Equal to (<=) 12 at Week 26
Tijdsspanne: Week 26

Percentage of participants with MADRS total score <=12 at Week 26 was reported. A participant was defined as a remitter at a given time point if the MADRS total score was <=12 at that time point. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.

Week 26
Percentage of Participants With a >=50 Percent Improvement in MADRS Total Score and MADRS <=18 at Week 26
Tijdsspanne: Week 26

Percentage of participants with a >=50 percent improvement in MADRS total score and MADRS <=18 at Week 26 was reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.

Week 26
Percentage of Participants With >=7 Percent Weight Increase From Baseline at Week 26
Tijdsspanne: Week 26

Percentage of participants with >=7 percent weight increase from baseline at Week 26 was reported.

Week 26

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

15 september 2020

Primaire voltooiing (Werkelijk)

3 oktober 2023

Studie voltooiing (Werkelijk)

3 oktober 2023

Studieregistratiedata

Eerst ingediend

13 augustus 2020

Eerst ingediend dat voldeed aan de QC-criteria

13 augustus 2020

Eerst geplaatst (Werkelijk)

14 augustus 2020

Updates van studierecords

Laatste update geplaatst (Werkelijk)

13 november 2026

Laatste update ingediend die voldeed aan QC-criteria

11 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • CR108810
  • 42847922MDD3005 (Andere identificatie: Janssen Research & Development, LLC)
  • 2020-000341-14 (EudraCT-nummer)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical- trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren